{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Grohskopf_et_al.__2023_",
  "verified_evidence": [
    {
      "id": 3,
      "quote": "For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/9/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage like virus), and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus).",
      "supports_claim": true,
      "explanation": "The quote explicitly states that Flublok (RIV4) will contain hemagglutinin (HA) derived from the exact strains listed, which are the WHO- and FDA-recommended strains for the 2022-23 season. This directly supports the claim that Flublok ensures an identical antigenic match with the WHO- and FDA-selected flu strains, as it confirms the vaccine's composition matches the recommended strains for that season.",
      "presence_explanation": "The quote appears on page 19 of the document: 'For the 2022-23 season, U.S. cell culture based in activated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from \u2022 an influenza A/Wisconsin/588/2019 (H1 N1) pdm 09 like virus, \u2022 an influenza A/Darwin/9/2021 (H3 N2)-like virus, \u2022 an influenza B/Austria/1359417/2021 (Victoria lineage like virus), and \u2022 an influenza B/Phuket/3073/2013 (Yamagata lineage like virus).' The factual content, strain names, and vaccine types match the quote to verify, with only minor formatting differences (e.g., bullet points and line breaks).",
      "support_explanation": "The quote explicitly states that Flublok (RIV4) will contain hemagglutinin (HA) derived from the exact strains listed, which are the WHO- and FDA-recommended strains for the 2022-23 season. This directly supports the claim that Flublok ensures an identical antigenic match with the WHO- and FDA-selected flu strains, as it confirms the vaccine's composition matches the recommended strains for that season.",
      "original_relevance": "This quote specifies that Flublok (RIV4) will contain hemagglutinin derived from the exact strains selected for the 2022-23 season, which are the WHO- and FDA-recommended strains, directly affirming the claim of identical antigenic match."
    },
    {
      "id": 5,
      "quote": "All seasonal influenza vaccines expected to be available in the United States for the 2022-23 season are quad rival ent, containing hemagglutinin (HA) derived from one influenza A (H1 N1) pdm09 virus, one influenza A (H3 N2) virus, one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. In activated influenza vaccines (IIV4 s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available.",
      "supports_claim": true,
      "explanation": "The quote explicitly states that all seasonal influenza vaccines expected to be available in the US for 2022-23, including recombinant influenza vaccine (RIV4, which is Flublok), will contain hemagglutinin (HA) derived from the same four strains: one influenza A (H1N1)pdm09, one influenza A (H3N2), one influenza B/Victoria lineage, and one influenza B/Yamagata lineage. This directly supports the claim that Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains, as it confirms that the antigenic composition of Flublok matches that of all other vaccines and is based on the selected strains.",
      "presence_explanation": "The quote appears on page 3 of the document, with only minor formatting differences and some OCR artifacts in the original. The key content is present: 'All seasonal influenza vaccines expected to be available in the United States for the 2022-23 season are quad rival ent, containing hemagglutinin (HA) derived from one influenza A (H1 N1) pdm09 virus, one influenza A (H3 N2) virus, one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. In activated influenza vaccines (IIV4 s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available.' This matches the quote to verify, with only minor differences in spacing and line breaks.",
      "support_explanation": "The quote explicitly states that all seasonal influenza vaccines expected to be available in the US for 2022-23, including recombinant influenza vaccine (RIV4, which is Flublok), will contain hemagglutinin (HA) derived from the same four strains: one influenza A (H1N1)pdm09, one influenza A (H3N2), one influenza B/Victoria lineage, and one influenza B/Yamagata lineage. This directly supports the claim that Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains, as it confirms that the antigenic composition of Flublok matches that of all other vaccines and is based on the selected strains.",
      "original_relevance": "This quote confirms that all available vaccines, including Flublok (RIV4), will contain HA antigens derived from the same four WHO- and FDA-selected strains, supporting the claim of identical antigenic match."
    }
  ],
  "verification_stats": {
    "total_verified": 2
  },
  "image_evidence": []
}